Cytokinetics CEO sells 7,500 shares at $77.21
Cytokinetics Inc. President and CEO Robert I. Blum reported an open-market sale of 7,500 shares of common stock at $77.21 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cytokinetics Inc. President and CEO Robert I. Blum reported an open-market sale of 7,500 shares of common stock at $77.21 per share. Following this sale, he holds 392,830 shares directly. Separate trust holdings reported as of the same date each hold 2,083 shares indirectly.
Insider Trade Summary 10b5-1
Net Seller: 7,500 shares
Net Sell
3 txns
Insider
Blum Robert I
Role
President & CEO
Sold
7,500 shs ($579K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 7,500 | $77.21 | $579K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 392,830 shares (Direct);
Common Stock — 2,083 shares (Indirect, by Trust 1);
Common Stock — 2,083 shares (Indirect, by Trust 2)
Footnotes (2)
- F1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
- F2. Shares held by The Brittany Blum 2003 Irrevocable Trust.
Key Figures
Shares sold: 7,500 shares
Sale price: $77.21 per share
Direct holdings after sale: 392,830 shares
+2 more
5 metrics
Shares sold
7,500 shares
Open-market sale of common stock on May 27, 2026
Sale price
$77.21 per share
Price for the 7,500-share common stock sale
Direct holdings after sale
392,830 shares
Common stock directly owned by CEO after transaction
Trust 1 holdings
2,083 shares
Common stock held by The Bridget Blum 2003 Irrevocable Trust
Trust 2 holdings
2,083 shares
Common stock held by The Brittany Blum 2003 Irrevocable Trust
Key Terms
Form 4, open-market sale, indirect ownership, Irrevocable Trust
4 terms
Form 4 regulatory
"Insider transaction is reported on Form 4 for Cytokinetics."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
open-market sale financial
"The 7,500-share transaction is classified as an open-market sale."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
indirect ownership financial
"Trust-held shares are disclosed as indirect ownership related to Robert Blum."
Irrevocable Trust financial
"Shares are held by The Bridget Blum 2003 Irrevocable Trust and a similar trust."
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Cytokinetics (CYTK) CEO Robert Blum report in this Form 4?
Robert Blum reported an open-market sale of 7,500 shares of Cytokinetics common stock. The sale was executed at a price of $77.21 per share, and the transaction is classified as a non-derivative disposition of directly held common shares.
Are there any indirect Cytokinetics holdings reported for the CEO in this Form 4?
Yes. The filing reports 2,083 Cytokinetics shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust, both shown as indirect ownership positions associated with Robert Blum on the same date.
Does this Cytokinetics Form 4 show any option exercises or derivative transactions?
The Form 4 does not report any derivative transactions or option exercises. All reported activity involves common stock, with one non-derivative open-market sale and separate entries reflecting indirect common stock holdings in two irrevocable trusts as of the stated date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
